Department of Cardiology, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China (mainland).
Department of Preventive Medicine, Changzhi Medical College, Changzhi, Shanxi, China (mainland).
Med Sci Monit. 2018 Jun 18;24:4175-4182. doi: 10.12659/MSM.908732.
BACKGROUND Reperfusion injury is one of the leading causes of myocardial cell death and heart failure. This study was performed to identify new candidate lipid biomarkers for the purpose of optimizing the diagnosis of myocardial ischemia reperfusion (I/R) injury, assessing the severity of myocardial I/R injury and trying to find the novel mechanism related to lipids. MATERIAL AND METHODS Forty patients who were diagnosed with ST-segment elevation myocardial infarction (STEMI) were randomly selected for this study. Serum samples from all the patients with STEMI were collected at 3 time periods: after STEMI diagnosis but prior to reperfusion (T0); and then at 2 hours (T2) and 24 hours (T24) after the end of the percutaneous coronary intervention procedure. Plasma lipidomics profiling analysis was performed to identify the lipid metabolic signatures of myocardial I/R injury using lipidomics. RESULTS Sixteen types of potential lipid biomarkers at different time periods (T0, T2, T24) were identified by using lipidomics technology. The T0 time periods exhibited 16 differentially metabolized lipid peaks in the patients after STEMI diagnosis but prior to reperfusion. With the increase of reperfusion times, the contents of these 16 lipid biomarkers decreased gradually, but there was a 1.5- to 2-fold increase of those 16 lipid biomarkers contents at T2 compared with T24. CONCLUSIONS Lipidomics analysis demonstrated differential change before and after reperfusion, suggesting a potential role of some of these lipids as biomarkers for optimizing the diagnosis of myocardial I/R, as well as for therapeutic targets against myocardial I/R injury.
背景:再灌注损伤是心肌细胞死亡和心力衰竭的主要原因之一。本研究旨在鉴定新的候选脂质生物标志物,目的是优化心肌缺血再灌注(I/R)损伤的诊断,评估心肌 I/R 损伤的严重程度,并寻找与脂质相关的新机制。
材料和方法:本研究随机选择了 40 名诊断为 ST 段抬高型心肌梗死(STEMI)的患者。所有 STEMI 患者的血清样本均在 3 个时间点采集:STEMI 诊断后但在再灌注之前(T0);然后在经皮冠状动脉介入治疗结束后 2 小时(T2)和 24 小时(T24)。采用脂质组学分析技术对心肌 I/R 损伤的脂质代谢特征进行分析。
结果:通过脂质组学技术,在不同时间点(T0、T2、T24)鉴定出 16 种潜在的脂质生物标志物。在 STEMI 诊断后但在再灌注之前,患者的 T0 时间点表现出 16 种差异代谢脂质峰。随着再灌注次数的增加,这 16 种脂质生物标志物的含量逐渐降低,但与 T24 相比,T2 时这 16 种脂质生物标志物的含量增加了 1.5 至 2 倍。
结论:脂质组学分析显示再灌注前后的差异变化,表明其中一些脂质作为心肌 I/R 诊断的优化生物标志物,以及心肌 I/R 损伤治疗靶点具有潜在作用。
Eur Heart J Acute Cardiovasc Care. 2015-12-21
Eur Heart J Acute Cardiovasc Care. 2017-5-23
Circ Cardiovasc Imaging. 2016-12
J Cardiothorac Surg. 2025-7-9
Front Microbiol. 2023-8-17
iScience. 2022-1-29
Metabolites. 2021-10-6
Biochem Biophys Rep. 2021-6-10
Med Sci Monit. 2018-1-12
Am J Case Rep. 2016-11-30
Anal Bioanal Chem. 2015-7
Bioanalysis. 2014-2